Results 81 to 90 of about 11,700 (225)

Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease

Responsive Materials, Volume 3, Issue 4, November 2025.
This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang, Jiayi Hou, Yameng Zhao, Yiwen Wang, Kexin Wang, Siyu Li, Yange Wang, Jiehao Zhang, Shenao Ding, Chenxu Zhang, Zongming Song, Ye Tao   +11 more
wiley   +1 more source

Pharmacologic Manipulation of Conventional Outflow Facility in Ex Vivo Mouse Eyes [PDF]

, 2012
PURPOSE. Mouse models are useful for glaucoma research, but it is unclear whether intraocular pressure (IOP) regulation in mice operates through mechanisms similar to those in humans.
Bertrand, J, Boussommier-Calleja, A, Ethier, CR, Overby, DR, Stamer, WD, Woodward, DF   +5 more
core   +1 more source

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients

Clinical Ophthalmology, 2010
Michael J Miyashiro1, Samuel C Lo2, Jeanette A Stewart3, William C Stewart31Ludwig Ophthalmology Centre, Hilo, HI, USA; 2Private Practice, Honolulu, HI, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas, TX, USAObjective: To examine the efficacy ...
Michael J Miyashiro, Samuel C Lo, Jeanette A Stewart, et al   +3 more
doaj  

A Patient with Corneal Epithelial Disorder That Developed after Administration of a Latanoprost Generic, but Not a Brand-Name Drug, Eye Drop

Case Reports in Ophthalmological Medicine, 2012
Background. We report a patient who developed corneal epithelial disorder repeatedly after changing the prescription from Xalatan eye drops (Pfizer Inc.) to Latanoprost eye drops (Kaken Pharmaceutical Co., Ltd.), both containing 0.005% latanoprost. Case
Yukihisa Takada, Yuka Okada, Norihito Fujita, Shizuya Saika   +3 more
doaj   +1 more source

Evaluation of Visual Field and Imaging Outcomes for Glaucoma Clinical Trials (An American Ophthalomological Society Thesis) [PDF]

, 2017
PURPOSE: To evaluate the ability of various visual field (VF) analysis methods to discriminate treatment groups in glaucoma clinical trials and establish the value of time-domain optical coherence tomography (TD OCT) imaging as an additional outcome ...
Cheng, Q., Crabb, D. P., Garway-Heath, D. F., Prah, P., Quartilho, A., Zhu, H.   +5 more
core   +1 more source

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study. [PDF]

, 2017
Objective To compare a fixed combination of 0.03% bimatoprost and 0.5% timolol (BTFC) with latanoprost monotherapy (LM) in treatment-naïve patients with open-angle glaucoma (OAG) and risk factors for glaucomatous progression.
GIFT study group, Gutierrez Díaz, Esperanza, Gutierrez Ortiz, Consuelo, Maltman, John, Millá, Elena, Morgan Warren, Robert J., Muñoz Negrete, Francisco J., Silva Cotta, Jose   +7 more
core   +1 more source

Immunologic Corneal Graft Rejection after Administration of Topical Latanoprost: a Report of Two Patients

Journal of Ophthalmic & Vision Research, 2011
Purpose: To report endothelial corneal graft rejection after administration of topical latanoprost eye drops. Case Report: Two eyes of two patients with a history of multiple intraocular procedures prior to penetrating keratoplasty developed endothelial
Kouros Nouri-Mahdavi, Mohammad-Ali Javadi, Mohammad-Reza Jafarinasab   +2 more
doaj  

Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma [PDF]

, 2014
The aim of the study was to evaluate the long-term 24-hour intraocular pressure (IOP) efficacy of travoprost monotherapy in primary open-angle glaucoma ...
Biagioli, Elena, Centofanti, M, Floriani, Irene, Katsanos, Andreas, Konstas, Anastasios, Quaranta, Luciano, Riva, Ivano   +6 more
core   +1 more source

Distribution of 14C-Latanoprost Following a Single Intracameral Administration Versus Repeated Topical Administration [PDF]

, 2020
Jie Shen, Rex Moats, Harvey Pollack, Michael R. Robinson, Mayssa Attar   +4 more
openalex   +1 more source

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials

Clinical Ophthalmology, 2014
Jonathan S Myers,1 Steven Vold,2 Fiaz Zaman,3 Julia M Williams,4 David A Hollander41Wills Eye Hospital, Philadelphia, PA, USA; 2Vold Vision, PLLC, Bentonville, AR, USA; 3Houston Eye Associates, Houston, TX, USA; 4Allergan, Inc., Irvine, CA, USABackground:
Myers JS, Vold S, Zaman F, Williams JM, Hollander DA   +4 more
doaj